Inventiva (NASDAQ:IVA – Get Rating) had its price objective lowered by investment analysts at HC Wainwright from $42.00 to $36.00 in a research report issued to clients and investors on Friday, The Fly reports.
Inventiva Price Performance
IVA opened at $3.90 on Friday. The firm’s fifty day moving average is $4.54 and its two-hundred day moving average is $5.97. The company has a current ratio of 5.06, a quick ratio of 5.04 and a debt-to-equity ratio of 0.10. Inventiva has a twelve month low of $3.75 and a twelve month high of $15.78.
Institutional Investors Weigh In On Inventiva
An institutional investor recently raised its position in Inventiva stock. Yiheng Capital Management L.P. increased its stake in shares of Inventiva S.A. (NASDAQ:IVA – Get Rating) by 59.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,640,253 shares of the company’s stock after acquiring an additional 982,679 shares during the period. Inventiva comprises about 0.9% of Yiheng Capital Management L.P.’s portfolio, making the stock its 21st largest position. Yiheng Capital Management L.P. owned about 6.46% of Inventiva worth $14,970,000 as of its most recent filing with the Securities & Exchange Commission. 22.29% of the stock is currently owned by institutional investors and hedge funds.
Inventiva Company Profile
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH.
- Get a free copy of the StockNews.com research report on Inventiva (IVA)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.